News2022-09-10T09:06:57+00:00

Normax Press Room

Normax secures €300,000,000 capital commitment from Global Emerging Markets (GEM) for research and development and manufacturing of mRNA Vaccines for transformative global social impact

Normax plans to use capital finance to scale mRNA Vaccine Research and Development with Vax Factory Manufacturing for Transformative Social Impact on Infectious Diseases, Rare Diseases, Cancers and Pandemic Preparedness July 11, 2022, 12:00 PM Greenwich Mean Time (GMT) - PRESS RELEASE. NOT AN OFFER. SEE DISCLAIMER. DUBLIN, Ireland -- The mRNA vaccine technology company Normax Biomed Limited (“Normax”), today announced a €300 Million investment commitment from GEM Global Yield LLC SCS (“GEM”), the $3.4 Billion, Luxembourg based, private [...]

July 11, 2022|
Media Contact

Berkeley Communications
+44 118 909 0909
normax@berkeleypr.com

Download Press Kit
Berkeley PR
Normax In-the-News
Go to Top